MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Celcuity Interest Expense 2011-2026 | CELC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Celcuity
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.11 M | 1.26 M | 120 | 159 | 111 | 452 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.11 M | 111 | 637 K |
Quarterly Interest Expense Celcuity
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.34 M | 2.26 M | 1.4 M | - | 1.37 M | 1.31 M | 1.24 M | - | 538 K | 455 K | 435 K | - | 433 K | 391 K | 24 | - | 28 | 31 | 33 | - | 39 | 41 | 43 | - | 65 | - | - | - | 265 K | 187 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.34 M | 24 | 649 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Bioventus
BVS
|
-1.45 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
DexCom
DXCM
|
177 M | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.77 | 0.61 % | $ 447 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
81 M | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 9.0 | -0.99 % | $ 255 M |  Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.33 | 4.72 % | $ 399 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 173.74 | 0.49 % | $ 24.2 B |  Schweiz |
 |
Personalis
PSNL
|
24 K | $ 6.72 | 1.97 % | $ 398 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
9.32 M | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.42 | 0.71 % | $ 3.81 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.19 | 2.59 % | $ 826 M | USA |